Dietary Restriction of Serine and Glycine May Have Antitumor Effects [Metabolism]
Serine/glycine restriction extends survival in mouse models of lymphoma and intestinal cancer. (Source: Cancer Discovery)
Source: Cancer Discovery - June 1, 2017 Category: Cancer & Oncology Tags: Metabolism Source Type: research
Integrated Profiling Uncovers Lymphoma Immunoglobulin Neoantigens [Lymphoma]
CD4+ T cells specific for immunoglobulin-derived neoantigens target autologous lymphoma cells. (Source: Cancer Discovery)
Source: Cancer Discovery - June 1, 2017 Category: Cancer & Oncology Tags: Lymphoma Source Type: research
The RNA-Binding Protein SYNCRIP Promotes Leukemogenesis [Leukemia]
Depletion of the RNA-binding protein (RBP) SYNCRIP promotes leukemic cell differentiation and apoptosis. (Source: Cancer Discovery)
Source: Cancer Discovery - June 1, 2017 Category: Cancer & Oncology Tags: Leukemia Source Type: research
VISTA Upregulation May Promote Resistance to CTLA-4 Blockade [Immunotherapy]
CTLA-4 blockade with ipilimumab activates the immune inhibitory VISTA checkpoint in prostate cancer. (Source: Cancer Discovery)
Source: Cancer Discovery - June 1, 2017 Category: Cancer & Oncology Tags: Immunotherapy Source Type: research
Targeting CDK7 or BRD4 Blocks Diffuse Intrinsic Pontine Glioma Growth [Glioma]
Diffuse intrinsic pontine glioma (DIPG) is sensitive to transcriptional disruption via CDK7/BRD4 blockade. (Source: Cancer Discovery)
Source: Cancer Discovery - June 1, 2017 Category: Cancer & Oncology Tags: Glioma Source Type: research
Blinatumomab Has Activity in Patients with TKI-Refractory Ph+ ALL [Structural Biology]
Blinatumomab achieved complete remission with full or partial hematologic recovery in 36% of patients. (Source: Cancer Discovery)
Source: Cancer Discovery - June 1, 2017 Category: Cancer & Oncology Tags: Structural Biology Source Type: research
Profiling Differential Responses to Pan-HER Inhibition [News in Brief]
Findings from the phase II SUMMIT basket trial indicate that among patients with solid cancers harboring HER2/3 mutations, responses to the investigational pan-HER inhibitor neratinib vary by specific alteration and tumor type. Neratinib showed promising single-agent activity in breast, biliary tract, and cervical cancers, but was ineffective against bladder and colorectal cancers; among a small subset of patients with HER3 mutations, no responses were seen. (Source: Cancer Discovery)
Source: Cancer Discovery - June 1, 2017 Category: Cancer & Oncology Tags: News in Brief Source Type: research
Immunotherapy Combo Offers Slight Survival Benefit in Melanoma [News in Brief]
Data on 2-year survival in the phase III CheckMate 067 trial testing nivolumab plus ipilimumab showed a slight survival benefit for the combination over nivolumab monotherapy—but the difference may not be dramatic enough to justify using the combination given the added side effects. (Source: Cancer Discovery)
Source: Cancer Discovery - June 1, 2017 Category: Cancer & Oncology Tags: News in Brief Source Type: research
Atezolizumab Extends Survival for Breast Cancer [News in Brief]
The anti–PD-L1 drug atezolizumab produced durable responses among 10% of patients with triple-negative breast cancer in a large phase I trial presented at the American Association for Cancer Research Annual Meeting 2017. The therapy proved safe, with the highest response rates seen in women who received the drug as a first-line therapy and in those with elevated PD-L1 levels and other tumor biomarkers. (Source: Cancer Discovery)
Source: Cancer Discovery - June 1, 2017 Category: Cancer & Oncology Tags: News in Brief Source Type: research
Coxsackievirus A21 Synergizes with Checkpoint Inhibitors [News in Brief]
Treatment with a combination of a proprietary formulation of coxsackievirus and either an anti–CTLA-4 or anti–PD-1 checkpoint inhibitor yielded a higher response rate in phase I testing for melanoma than any of these drugs given on their own. Because the viral therapy adds little toxicity, it might prove an effective part of a dual regimen, according to interim trial data presented at the American Association for Cancer Research Annual Meeting 2017. (Source: Cancer Discovery)
Source: Cancer Discovery - June 1, 2017 Category: Cancer & Oncology Tags: News in Brief Source Type: research
CAR T-cell Therapy: Defining Response Characteristics [News in Brief]
Findings from a phase I study suggest that the durability of patients' response to CAR T-cell therapy, and their long-term survival, are influenced by whether they have minimal residual or morphologic disease prior to treatment. The former fared better overall, and also experienced less-severe side effects from this form of immunotherapy. (Source: Cancer Discovery)
Source: Cancer Discovery - June 1, 2017 Category: Cancer & Oncology Tags: News in Brief Source Type: research
Analysis Suggests Wider Use for PARP Inhibitors [News in Brief]
Researchers have developed a new tool, HRDetect, to pinpoint tumors that display BRCA deficiency but don't harbor BRCA1/2 mutations. Evaluating their method in breast, ovarian, and pancreatic cancers, they identified patients whose tumors were potentially vulnerable to PARP inhibition but who didn't carry these mutations. (Source: Cancer Discovery)
Source: Cancer Discovery - June 1, 2017 Category: Cancer & Oncology Tags: News in Brief Source Type: research
Study Suggests Treatment Approaches for Cholangiocarcinomas [News in Brief]
A comprehensive genome profile of cholangiocarcinoma reveals that the tumors fall into four molecular classes. The study suggests that patients with IDH1/2 mutations could benefit from drugs that inhibit oxidative phosphorylation or that target mutations in chromatin remodeling genes. The work also shows that some liver cancers are closely related to cholangiocarcinomas. (Source: Cancer Discovery)
Source: Cancer Discovery - June 1, 2017 Category: Cancer & Oncology Tags: News in Brief Source Type: research
Avelumab Impresses in Merkel Cell Carcinoma [News in Brief]
The PD-L1 inhibitor avelumab—approved by the FDA in March for the treatment of Merkel cell carcinoma—demonstrated a high number of durable responses in an international, open-label, prospective phase II study. The results of the study, which supported the FDA's decision, were presented in April at the American Association for Cancer Research (AACR) Annual Meeting 2017. (Source: Cancer Discovery)
Source: Cancer Discovery - June 1, 2017 Category: Cancer & Oncology Tags: News in Brief Source Type: research
Nod for Atezolizumab in Advanced Bladder Cancer [News in Brief]
The FDA approved atezolizumab to treat advanced bladder cancer when cisplatin chemotherapy is contraindicated. The approval offers a potentially more effective alternative to carboplatin-based chemotherapy for frail, elderly patients. (Source: Cancer Discovery)
Source: Cancer Discovery - June 1, 2017 Category: Cancer & Oncology Tags: News in Brief Source Type: research
